Real-world study reports 3-year dupilumab outcomes in pediatric eczema

A multicenter prospective cohort study (BioDay Registry, Netherlands) followed 309 pediatric patients aged 16 or younger with moderate to severe atopic dermatitis treated with dupilumab for up to 3 years. The study reported sustained low disease severity and pruritus scores, with three-year drug survival of 80.1%; ocular surface disease was the most common adverse event, and discontinuation occurred in 16.2% of patients, mainly due to ineffectiveness, adverse events, or administration problems. The study noted that younger children (6 months to 5 years) reported higher pruritus and quality-of-life impairment scores and discontinued treatment more often due to administration difficulties compared with older age groups.

Most relevant for: Pediatric patients with moderate to severe atopic dermatitis being treated with dupilumab, particularly across different pediatric age groups from infancy through adolescence.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.